SonoSite’s NanoMaxx® ultrasound system is proving a key asset for ambulance and helicopter paediatric retrievals across Scotland, helping to ensure the safe transfer of patients from remote, rural sites.
Trichomonias, with an estimated 187 million cases, and Chlamydia with around 100 million, are the most prevalent sexually transmitted diseases (STDs), according to the World Health Organisation (WHO). There are approximately 36 million cases each of gonorrhoea and syphilis. HIV1/2 cases are around 34 million. Report: Cynthia Keen
Dr Rip Gangahar, Trauma Lead for the Pennine Acute Hospitals NHS Trust and Chair of the International Federation for Emergency Medicine Ultrasound Group, discusses the past, present and future of ultrasound training for emergency medicine.
Infection, the tightest space and fast scanning are the three biggest things clinicians must tackle today in a point of care (POC) environment.
Given their quality, small size, portability and robustness, SonoSite point-of-care ultrasound systems play vital roles in hectic A&E and surgical departments, and also in monitoring patients in transit.
Once considered an add-on examination, CEUS expands diagnostic capabilities and is leading to new insights. Where contrast enhanced ultrasound (CEUS) is restricted to radiologists, or performed only by trained technicians, its utilisation has stabilised, taking its place among more established imaging modalities. Report: John Brosky
Treat a proficiency testing (PT) sample just like a patient sample. But don't. That has been the message labs have struggled with and in some cases lost their CLIA certificates over.
Health analysts have predicted that DNA sequencing will shift from a laboratory-based setup to point of care testing within the next five years.
New molecular technologies to screen drug-resistant TB are replacing, for example, culture-based tests that are slow, require experienced personnel, and need stringent microbiological safety precautions.
For several decades pathologists worldwide have been under increasing pressure to handle a steady increase in laboratory tests with a steady decrease in finance and staff.
Scientists in the UK are working to develop a hand-held testing device to provide same day diagnosis from a patient’s bedside. The device will use disposable cartridges and utilise printed circuit board technology (PCB) that will allow a fast and low-cost diagnosis.
Two companies with similar core values, providing high quality products for acute care and point-of-care testing worldwide.
‘Physicians and clinicians treating patients at the point of care (POC) can benefit greatly from easy access to materials and resources via their handheld devices,’ comments Jamie Gramz, Director of Global Marketing at Siemens Healthcare Diagnostics.
Ahead of regulatory approval that is expected before the end of the year, Trinity Biotech chose Medica to present the novel point-of-care (POC) analyzer Meritas with the Troponin I (TnI) that are expected to disrupt a €700 million market.
Over the past 10 years the use of point-of-care testing (POCT) in in European and North American hospitals has steadily increased, stimulated by the objectives of accelerating diagnostic treatment, increasing efficiency and improving patient outcomes, Cynthia E. Keen reports
In intensive care units (ICUs) little can be automated to relieve staff pressures – with the exception of point of care testing (POCT)
Nat Whitney, President of Whitney Research, sums up the ups and downs of the international IVD market and reports on a fitting finale for 17 years of dedicated service
Frost & Sullivan is carefully tracking the transforming global point-of-care testing (POCT) market, offering latest information on key opportunities and critical unmet needs by region
About 500,000 people in France people suffer heart failure (HF). In Europe the figure is six million and the same in the USA.
Increasing demand for Point of Care Testing (POCT) devices leads to an increasing number of nurses and physicians working with unfamiliar equipment. Laboratory-quality test results are available in doctor’s surgeries, out-patient clinics and hospital departments. However, how can a high and comparable quality standard for POCT be guaranteed?
EKF Diagnostics has recently marked the production at its manufacturing facility in Barleben, Germany, of the 33,333rd Hemo Control, its globally successful haemoglobin point-of-care analyser, since its launch in 2003.
Demand is increasing for point of care (POC) diagnostic testing, particularly for tests that help foster clinical decision-making within 30 minutes or less.
EKF Diagnostics, worldwide manufacturer of point-of-care diagnostic tools, organ injury biomarkers and assays, has announced the launch of a new division to focus on molecular and companion diagnostics.
Julian Baines, Group CEO of EKF Diagnostics Holdings plc, considers the present role of point of-care tests and their potential value to health services
Bringing diagnostics to the patient: Point-of-Care-Testing (POCT) is all about examinations close to the patient – in the hospital ward, at the GP, in the ambulance or even in the patient's home. Keep reading for new developments and applications from rapid medical laboratory tests to mobile imaging solutions.